Abstract:To investigate the efficacy and the roles of immune interruptions on blocking mother-to-infant transmission of hepatitis B virus (HBV),667 pregnant women who were seropositive for hepatitis B surface antigen (HBsAg) were enrolled. According to the lab test results of HBV e antigen (HBeAg) and HBV DNA in the mothers, the mothers were divided into either HBeAg-positive group or HBeAg-negative group, and either HBV DNA-positive group or HBV DNA-negative group. Depending on whether the mothers were receiving hepatitis B immunoglobulin (HBIG) once a month during the third trimester of pregnancy, they were divided into either the HBIG-receiving group or the non-HBIG-receiving group. All infants received regular passive and active HBV immunization after birth. Infant serum HBV markers were determined 8-12 months after birth. Twenty infants born to HBsAg-positive mothers were infected with HBV and the failure rate of immune interruptions was 3.0%. The failure rate of immune interruptions in the HBeAg-positive group was 8.7%, which was significantly higher than that observed in HBeAg-negative group 0.2% (P<0.001). However, the HBV surface antibody (HBsAb) positive rates of the infants between the two groups were not statistically different (P=0.988). The overall failure rate of immune interruptions of infants born to the HBV DNA-positive group was 8.1%, and the infants infected with HBV were all born to the mothers whose serum HBV DNA levels were above 6 log10 copies/ml. There were no statistical differences in the incidence of perinatal HBV infection between mothers receiving HBIG and those not receiving HBIG (3.7% vs 2.7%, P=0.479). No statistical differences were seen in HBsAb positive rates versus vaccination of the infants between the two groups (84.4% vs 82.4%, P=0.519). Among HBeAg-positive pregnant women receiving HBIG, the failure rate of immune interruptions in their infants was 8.4%, compared with 8.9% in those who did not receive HBIG, with no statistical differences (P=0.892). Importantly, 10 out of 11 infants who were infected with HBV were already serum HBsAg-positive immediately after birth, suggesting intrauterine infection either via venous or cord blood. These results indicate that preventative vaccine immunization plus HBIG administration does not block intrauterine transmission of HBV. Approaches to decrease the serum HBV DNA load in pregnant women by antiviral treatment may efficiently block mother-to-infant transmission.

Post-vaccination serological test results of infants at risk of perinatal transmission of hepatitis B using an intensified follow-up programme in a London centre.

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

The optimal interval for post-vaccination serological test in infants born to mothers with positive hepatitis B surface antigen

Prevention of vertical transmission of hepatitis B: A retrospective review of a 5-year maternal-infant cohort in London

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Prevention of perinatal hepatitis B virus transmission: are we following guidelines?

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Uptake of perinatal immunoprophylaxis for infants born to women with a record of hepatitis B in Victoria (2009-2017)

The antibody persistence after immunisation with hepatitis B vaccine combined with different doses of hepatitis B immunoglobulin among infants born by HBsAg positive mothers: a three-year following-up study

The efficacy of immune interruptions on blocking mother-toinfant transmission of hepatitis B virus

Long-term Efficacy of Infant Hepatitis B Immunization Program

Long-term Protection of Infants Against Hepatitis B by Neonatal Immunoprophylaxis Born from Mothers Infected with Hepatitis B Virus

Protective Effect of an Improved Immunization Practice of Mother-To-Infant Transmission of Hepatitis B Virus and Risk Factors Associated with Immunoprophylaxis Failure

[Long-Term Efficacy Study of Hepatitis B Vaccination in Newborns--results of 11 Years' Follow-Up].

Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration of Maternal Screening and Infant Post-vaccination Serologic Testing

Long-term follow-up of a vaccination program for infants born to HBsAg-positive mothers in Stockholm County, Sweden

The dynamic changes in serologic HBV markers in infants born by HBsAg-carrying mothers

Long-Term Efficacy Of Active Postexposure Immunization Of Infants For Prevention Of Hepatitis-B Virus-Infection

A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants

Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study